[go: up one dir, main page]

DK2306986T3 - Prodrugs og lægemiddelmakromolekylkonjugater med styret lægemiddelfrigivelsesrater - Google Patents

Prodrugs og lægemiddelmakromolekylkonjugater med styret lægemiddelfrigivelsesrater Download PDF

Info

Publication number
DK2306986T3
DK2306986T3 DK09771199.8T DK09771199T DK2306986T3 DK 2306986 T3 DK2306986 T3 DK 2306986T3 DK 09771199 T DK09771199 T DK 09771199T DK 2306986 T3 DK2306986 T3 DK 2306986T3
Authority
DK
Denmark
Prior art keywords
formula
drug
optionally substituted
compound
macromolecule
Prior art date
Application number
DK09771199.8T
Other languages
English (en)
Inventor
Daniel V Santi
Gary Ashley
Brian Hearn
Original Assignee
Prolynx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolynx Llc filed Critical Prolynx Llc
Application granted granted Critical
Publication of DK2306986T3 publication Critical patent/DK2306986T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/33317—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (14)

  1. PRODRUGS OG LÆGEMIDDELMAKROMOLEKYLKONJUGATER MED STYRET LÆGEMIDDELFRIGIVELSESRATER
    1. Forbindelse med formlen
    hvor Z er resten af et makromolekyle; L' er resten af en linker; D er resten af et lægemiddel; X er O eller S; A er alkenylen (C2), aryl eller fraværende; hver R1 og R2 uafhængigt er H; CN; N02; eventuelt substitueret aryl; eventuelt substitueret heteroaryl; eventuelt substitueret alkenyl; eventuelt substitueret alkynyl eller hver R1 og R2 uafhængigt er COR3 eller SOR3 eller S02R3, hvor R3 er H eller eventuelt substitueret alkyl; eventuelt substitueret aryl; eventuelt substitueret heteroaryl; eventuelt substitueret alkenyl; eventuelt substitueret alkynyl eller OR eller NR2, hvor hver R uafhængigt er H eller eventuelt substitueret alkyl; eller hver R1 og R2 uafhængigt er SR4, hvor R4 eventuelt er substitueret alkyl; eventuelt substitueret aryl; eventuelt substitueret heteroaryl; eventuelt substitueret alkenyl eller eventuelt substitueret alkynyl; hvor de eventuelle substituenter er udvalgt fra gruppen bestående af elektrondonerende grupper, såsom CrC4-alkyl; Ci-C4-alkoxy; Ci-C4-alkylthio; amino; alkylamino og dialkylamino; og elektronfraspaltelige grupper, såsom halogen; difLuormethyl; trifluormethyl; nitro; cyano; C(0)R, hvor R er H, Ci-C4-alkyl, Ci-C4-alkoxy eller -amino; og SOR og S02R, hvor R er CrC4-alkyl, aryl eller heteroaryl, hvor talrige sådanne eventuelle substituenter kan være bundet til aryl- og heteroarylringe, hvilke talrige substituenter kan være de samme eller forskellige; hvor R1 og R2 kan samles for at danne en 3-8-leddet ring; og hvor både R1 og R2 kan være H; hvor R5 er H eller alkyl (Ci_6).
  2. 2. Forbindelse ifølge krav 1, hvor R5 er H.
  3. 3. Forbindelse ifølge krav 1, hvor A er alkenylen eller fraværende.
  4. 4. Forbindelse ifølge et hvilket som helst af kravene 1-3, hvor linkerresten er en bivalent kæde med en molekylvægt på mellem 14 Da og 20 kDa, der kan indbefatte umættethed, heteroatomer, ringstrukturer, aromatiske dele og/eller heteroaromatiske dele, der kovalent binder Z til det resterende af molekylet.
  5. 5. Forbindelse ifølge krav 4, hvor linkeren er et peptid eller et pseudopeptid og/eller omfatter triazol og/eller phenylen og/eller en rest af maleimido.
  6. 6. Forbindelse ifølge et hvilket som helst af kravene 1-5, hvor makromolekylet er et antistof, et polysaccharid, en albumin eller en syntetisk polymer, såsom polyethylenglycol (PEG).
  7. 7. Forbindelse ifølge et hvilket som helst af kravene 1-6, hvor lægemidlet er et peptid, en nukleinsyre eller et lille molekyle.
  8. 8. Forbindelse ifølge et hvilket som helst af kravene 1-7, hvor én af R1 og R2 er CN, eller hvor mindst én af R1 og R2 omfatter phenyl eller phenylen, eller hvor én af R1 og R2 er S02R3 og den anden er H, alkyl eller phenyl.
  9. 9. Forbindelse med formlen
    hvor R1, R2, R5, A, X og D er som defineret i et hvilket som helst af kravene 1, 2, 3, 7 eller 8, og hvor L er en linkergruppe, der kan binde til et makromolekyle.
  10. 10. Forbindelse med formlen
    hvor R1, R2, R5, A, X, Z og L' er defineret som i krav 1, 2, 3, 4, 5, 6 eller 8.
  11. 11. Farmaceutisk sammensætning, der omfatter forbindelsen ifølge et hvilket som helst af kravene 1-9.
  12. 12. Forbindelse ifølge et hvilket som helst af kravene 1-9 til anvendelse som et medikament.
  13. 13. Fremgangsmåde til fremstilling af en forbindelse med formlen (3) som defineret i krav 1, hvilken fremgangsmåde omfatter omsætning af en forbindelse med formlen (2) som defineret i krav 9 med et makromolekyle, eller hvilken fremgangsmåde omfatter omsætning af en forbindelse med formlen (4) som defineret i krav 10 med et lægemiddel under forhold, hvor lægemidlet er koblet til forbindelsen med formlen (4).
  14. 14. Fremgangsmåde til fremstilling af en forbindelse med formlen (2) som defineret i krav 9, hvilken fremgangsmåde omfatter omsætning af en forbindelse med formlen (1):
    hvor R1, R2, R5, A og X er defineret som i krav 1, 2, 3 eller 8, og hvor L er en linkergruppe, der kan binde til et makromolekyle; med et lægemiddel under forhold, hvor lægemidlet er koblet til forbindelsen med formlen (1).
DK09771199.8T 2008-06-26 2009-06-26 Prodrugs og lægemiddelmakromolekylkonjugater med styret lægemiddelfrigivelsesrater DK2306986T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13314808P 2008-06-26 2008-06-26
US19205008P 2008-09-15 2008-09-15
PCT/US2009/048943 WO2009158668A1 (en) 2008-06-26 2009-06-26 Prodrugs and drug-macromolecule conjugates having controlled drug release rates

Publications (1)

Publication Number Publication Date
DK2306986T3 true DK2306986T3 (da) 2018-06-18

Family

ID=41444985

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09771199.8T DK2306986T3 (da) 2008-06-26 2009-06-26 Prodrugs og lægemiddelmakromolekylkonjugater med styret lægemiddelfrigivelsesrater

Country Status (7)

Country Link
US (2) US8680315B2 (da)
EP (1) EP2306986B1 (da)
JP (2) JP6084770B2 (da)
CN (1) CN102076331B (da)
DK (1) DK2306986T3 (da)
ES (1) ES2672526T3 (da)
WO (1) WO2009158668A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2566335T3 (da) * 2010-05-05 2016-10-03 Prolynx Llc Kontrolleret frigivelse af aktivstoffer fra makromolekylære konjugater
EP2566334B1 (en) * 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
EP2571496A4 (en) * 2010-05-05 2016-03-30 Prolynx Llc CONTROLLED RELEASE OF MEDICINE FROM DENIMERS
PT2729179T (pt) 2011-06-06 2020-11-25 Starpharma Pty Ltd Macromoléculas
WO2013036857A1 (en) * 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
CN103945870B (zh) 2011-09-07 2016-10-12 普罗林科斯有限责任公司 生物可降解交联的水凝胶
US20140256626A1 (en) * 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide
EP2850201A4 (en) * 2012-05-11 2016-08-31 Alexander Krantz Site-specific labeling and targeted administration of proteins for the treatment of cancer
EP3060230A4 (en) 2013-10-22 2017-06-14 Prolynx LLC Conjugates of somatostatin and its analogs
MX385651B (es) 2013-12-19 2025-03-18 Seagen Inc Enlazadores de carbamato de metileno para su uso en conjugados de farmacos dirigidos.
WO2016025752A1 (en) * 2014-08-14 2016-02-18 Prolynx Llc Reagents for thiol conjugation and conjugates formed therefrom
AU2015323769A1 (en) 2014-09-26 2017-04-13 Bayer Pharma Aktiengesellschaft Stabilized adrenomedullin derivatives and use thereof
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions
SG11201807832VA (en) * 2016-03-16 2018-10-30 Prolynx Llc Extended release conjugates of exenatide analogs
CN106177977B (zh) * 2016-07-11 2020-09-04 天津科技大学 一种抗肿瘤药物三元偶联物及合成和应用
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
EP3737383A4 (en) 2018-01-12 2021-12-15 Prolynx LLC SYNERGISTIC CANCER TREATMENT
AU2019306745B2 (en) 2018-07-19 2024-08-08 Starpharma Pty Ltd Therapeutic dendrimer
US12071517B2 (en) 2018-07-19 2024-08-27 Starpharma Pty Ltd. Therapeutic dendrimer
US20220257781A1 (en) * 2018-09-06 2022-08-18 Seikagaku Corporation Polymer conjugate bonded to tertiary amine compound or imine compound and production method therefor
US20220040318A1 (en) * 2018-09-28 2022-02-10 Seikagaku Corporation Primary amine compound or secondary amine compound-acidic polysaccharide conjugate and production method therefor
JP2022526985A (ja) * 2019-04-05 2022-05-27 プロリンクス エルエルシー 改良されたコンジュゲーションリンカー
CA3143584A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
CA3152373A1 (en) 2019-08-07 2021-02-11 Prolynx Llc Steam sterilization of hydrogels crosslinked by beta-eliminative linkers
CN110423355B (zh) * 2019-08-29 2021-09-14 武汉轻工大学 羧甲基化莲藕多糖-曲古霉素a轭合物的制备方法
JP7415047B2 (ja) 2020-04-22 2024-01-16 メルク・シャープ・アンド・ドーム・エルエルシー インターロイキン－２受容体βγｃ二量体について偏向され、非ペプチド性水溶性ポリマーにコンジュゲートされたヒトインターロイキン－２コンジュゲート
US20240261425A1 (en) * 2021-04-09 2024-08-08 Nanjing University Conjugate and the preparing method and use thereof
WO2024235071A1 (en) * 2023-05-16 2024-11-21 Nanjing University Conjugate and the preparation thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63501507A (ja) * 1986-05-16 1988-06-09 エカ　ノーベル　アクチェボラーグ 光学活性試薬および対掌体アミン化合物の測定法
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
DE4321946A1 (de) * 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
JP3192662B2 (ja) * 1996-07-31 2001-07-30 日研化学株式会社 ６―フェニルテトラヒドロ―１，３―オキサジン―２―オン誘導体及びそれを含む医薬組成物
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
JPH11130711A (ja) * 1997-10-24 1999-05-18 Teijin Ltd １α，２４，２５−トリヒドロキシビタミンＤ３類の合成中間体およびその製造法
AU1345600A (en) * 1998-11-12 2000-06-05 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
US6114566A (en) * 1999-05-24 2000-09-05 Board Of Trustees Operating Michigan State University 4-cyano-3-hydroxybutanoyl hydrazines, derivatives and process for the preparation thereof
JP2003528939A (ja) * 1999-09-03 2003-09-30 スクール オブ ファーマシー， ユニヴァーシティ オブ ロンドン 分解性ポリマー
US6861162B2 (en) 2002-08-28 2005-03-01 Cityu Research Ltd. Organic electroluminescence devices using pyrazolo[3,4b]quinoxaline derivatives
US20070027073A1 (en) 2003-04-08 2007-02-01 Menachem Rubinstein Long-acting derivatives of pyy agonists
PL1620118T3 (pl) * 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
GB0319759D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
ES2741524T3 (es) * 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
JP2006067889A (ja) 2004-09-01 2006-03-16 Japan Science & Technology Agency Ｐｅｏと二本鎖核酸のコンジュゲート
EP2292248A3 (en) 2005-03-03 2011-06-29 CovX Technologies Ireland Limited Anti-angiogenic compounds
CN101287835A (zh) 2005-08-17 2008-10-15 株式会社百奥尼 用于siRNA细胞内输送的siRNA-亲水性聚合物结合物及其方法
JP5224016B2 (ja) * 2006-03-10 2013-07-03 晃二 有光 感活性エネルギー線塩基発生剤、感活性エネルギー線塩基発生剤組成物、塩基反応性組成物及びパターン形成方法
US20100168443A1 (en) 2006-11-02 2010-07-01 University Of Virginia Patent Foundation Ethoid-Containing Compounds, Methods for Preparing Ethoid-Containing Compounds, and Methods of Use
PL2279007T3 (pl) * 2008-04-29 2016-11-30 Pegylowane związki rekombinowanego ludzkiego hormonu wzrostu

Also Published As

Publication number Publication date
CN102076331B (zh) 2013-12-18
WO2009158668A1 (en) 2009-12-30
US20140296476A1 (en) 2014-10-02
ES2672526T3 (es) 2018-06-14
EP2306986B1 (en) 2018-03-21
US9387254B2 (en) 2016-07-12
EP2306986A1 (en) 2011-04-13
EP2306986A4 (en) 2015-01-28
JP2015172078A (ja) 2015-10-01
US8680315B2 (en) 2014-03-25
US20110263502A1 (en) 2011-10-27
JP2011528654A (ja) 2011-11-24
JP6084770B2 (ja) 2017-02-22
CN102076331A (zh) 2011-05-25

Similar Documents

Publication Publication Date Title
DK2306986T3 (da) Prodrugs og lægemiddelmakromolekylkonjugater med styret lægemiddelfrigivelsesrater
US20210283264A1 (en) Polymeric Prodrugs with a Self-Immolative Linker
EP1434589B1 (en) Thioester-terminated water soluble polymers and method of modifying the n-terminus of a polypeptide therewith
JP4824404B2 (ja) 脂肪族生物分解性リンカーに基づく放出可能なポリマー複合体
CN104024306B (zh) 聚噁唑啉聚合物及其制备方法、这些聚合物的结合物及其医疗用途
JP2010503706A (ja) リジン系ポリマーリンカー
US10413594B2 (en) Conjugates of somatostatin analogues
EP2571496A1 (en) Controlled drug release from dendrimers
WO2017101883A1 (zh) 一种可在生理条件下降解的水凝胶
Simpson Synthesis, Characterization, and Assessment of Cationic Polypeptoids Toward Gene Delivery and Development of Air Stable N-Substituted N-Thiocarboxyanhydrides
CN101516336A (zh) 赖氨酸-基聚合连接基